JP2016505556A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505556A5
JP2016505556A5 JP2015545935A JP2015545935A JP2016505556A5 JP 2016505556 A5 JP2016505556 A5 JP 2016505556A5 JP 2015545935 A JP2015545935 A JP 2015545935A JP 2015545935 A JP2015545935 A JP 2015545935A JP 2016505556 A5 JP2016505556 A5 JP 2016505556A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015545935A
Other languages
English (en)
Japanese (ja)
Other versions
JP6490591B2 (ja
JP2016505556A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/074208 external-priority patent/WO2014093396A1/en
Publication of JP2016505556A publication Critical patent/JP2016505556A/ja
Publication of JP2016505556A5 publication Critical patent/JP2016505556A5/ja
Priority to JP2019034198A priority Critical patent/JP6889741B2/ja
Application granted granted Critical
Publication of JP6490591B2 publication Critical patent/JP6490591B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015545935A 2012-12-10 2013-12-10 抗血液樹状細胞抗原2抗体およびその使用 Active JP6490591B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019034198A JP6889741B2 (ja) 2012-12-10 2019-02-27 抗血液樹状細胞抗原2抗体およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261735362P 2012-12-10 2012-12-10
US61/735,362 2012-12-10
US201361763270P 2013-02-11 2013-02-11
US61/763,270 2013-02-11
PCT/US2013/074208 WO2014093396A1 (en) 2012-12-10 2013-12-10 Anti-blood dendritic cell antigen 2 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019034198A Division JP6889741B2 (ja) 2012-12-10 2019-02-27 抗血液樹状細胞抗原2抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2016505556A JP2016505556A (ja) 2016-02-25
JP2016505556A5 true JP2016505556A5 (https=) 2017-01-26
JP6490591B2 JP6490591B2 (ja) 2019-03-27

Family

ID=49883267

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015545935A Active JP6490591B2 (ja) 2012-12-10 2013-12-10 抗血液樹状細胞抗原2抗体およびその使用
JP2019034198A Active JP6889741B2 (ja) 2012-12-10 2019-02-27 抗血液樹状細胞抗原2抗体およびその使用
JP2021086053A Pending JP2021130677A (ja) 2012-12-10 2021-05-21 抗血液樹状細胞抗原2抗体およびその使用
JP2024006009A Pending JP2024045253A (ja) 2012-12-10 2024-01-18 抗血液樹状細胞抗原2抗体およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019034198A Active JP6889741B2 (ja) 2012-12-10 2019-02-27 抗血液樹状細胞抗原2抗体およびその使用
JP2021086053A Pending JP2021130677A (ja) 2012-12-10 2021-05-21 抗血液樹状細胞抗原2抗体およびその使用
JP2024006009A Pending JP2024045253A (ja) 2012-12-10 2024-01-18 抗血液樹状細胞抗原2抗体およびその使用

Country Status (25)

Country Link
US (3) US9902775B2 (https=)
EP (2) EP3686218A1 (https=)
JP (4) JP6490591B2 (https=)
KR (2) KR102344907B1 (https=)
CN (2) CN111961134B (https=)
AU (1) AU2013359419B2 (https=)
BR (1) BR122020023058B1 (https=)
CA (1) CA2893375A1 (https=)
CY (1) CY1122956T1 (https=)
DK (1) DK2928923T3 (https=)
EA (1) EA034757B1 (https=)
ES (1) ES2780398T3 (https=)
HR (1) HRP20200174T1 (https=)
HU (1) HUE047874T2 (https=)
IL (2) IL238804B (https=)
LT (1) LT2928923T (https=)
MX (1) MX363407B (https=)
NZ (1) NZ708033A (https=)
PL (1) PL2928923T3 (https=)
PT (1) PT2928923T (https=)
RS (1) RS60084B1 (https=)
SI (1) SI2928923T1 (https=)
SM (1) SMT202000193T1 (https=)
WO (1) WO2014093396A1 (https=)
ZA (1) ZA201503881B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2968561B1 (fr) 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire
AU2014365838B2 (en) * 2013-12-16 2021-01-14 The University Of North Carolina At Chapel Hill Depletion of plasmacytoid dendritic cells
US10294301B2 (en) * 2013-12-24 2019-05-21 Astellas Pharma Inc. Anti-human BDCA-2 antibody
FR3034420A1 (fr) * 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
FR3045386B1 (fr) 2015-12-16 2018-02-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation d'un anticorps dirige contre une proteine membranaire
MA44763A (fr) * 2016-04-28 2019-03-06 Biogen Ma Inc Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang
CN110218712B (zh) * 2016-06-02 2021-08-03 天津科技大学 磷脂酶d突变体及其在制备磷脂酸、磷脂酰丝氨酸中的应用
US11634495B2 (en) 2017-04-07 2023-04-25 Miltenyi Biotec B.V. & Co. KG Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303)
EP3785029A1 (en) * 2018-04-27 2021-03-03 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics
US12037398B2 (en) * 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
WO2021023793A1 (en) * 2019-08-05 2021-02-11 Capella Bioscience Ltd Anti bdca-2 antibodies
CA3203971A1 (en) 2020-12-03 2022-06-09 Biogen Ma Inc. Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus
JP7326584B2 (ja) 2020-12-17 2023-08-15 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗hla-g抗体及びその使用
CN113484512B (zh) * 2021-06-01 2023-06-27 中国农业科学院油料作物研究所 黄曲霉毒素风险预警智能感知卡及其应用
TW202400652A (zh) 2022-05-25 2024-01-01 大陸商映恩生物製藥(蘇州)有限公司 抗bdca2抗體及其用途
WO2024010118A1 (ko) * 2022-07-07 2024-01-11 주식회사 유틸렉스 항 bdca-2 항체 및 이의 용도
CN120475994A (zh) * 2022-12-28 2025-08-12 映恩生物科技(上海)有限公司 抗bdca2抗体-药物偶联物及其用途
WO2024230774A1 (en) * 2023-05-10 2024-11-14 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Bdca2-targeting antibodies and uses thereof
CN119119267A (zh) * 2023-06-12 2024-12-13 三生国健药业(上海)股份有限公司 抗bdca2抗体
CN121889498A (zh) 2023-09-05 2026-04-17 上海宏成药业有限公司 抗bdca-2特异性抗体及其用途
WO2025091023A1 (en) * 2023-10-27 2025-05-01 Northwestern University Engineered cell transfected by all-in-one vector for therapeutic agents production and delivery and applications thereof
CN120098124A (zh) * 2023-12-05 2025-06-06 苏州普乐康医药科技有限公司 一种抗bdca-2抗体及其制备方法和应用
CN118667008A (zh) * 2024-05-24 2024-09-20 深圳科兴药业有限公司 靶向bdca2的抗体或其抗原结合片段及其应用
WO2026008012A1 (zh) * 2024-07-04 2026-01-08 杭州博之锐生物制药有限公司 抗bdca2抗体及其用途
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用
CN119591712B (zh) * 2024-11-27 2025-11-21 纽迈生物科技(苏州)有限公司 靶向人类浆细胞样树突状细胞的单克隆抗体及其应用

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6201671B1 (en) 1998-12-04 2001-03-13 International Business Machines Corporation Seed layer for a nickel oxide pinning layer for increasing the magnetoresistance of a spin valve sensor
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7030228B1 (en) * 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
AU785198B2 (en) * 1999-11-15 2006-11-02 Miltenyi Biotec B.V. & Co. KG Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognised thereby and cells obtained thereby
US20070148171A1 (en) 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003254019A1 (en) * 2002-07-18 2004-02-09 Dana-Farber Cancer Institute, Inc. Compositions and methods to select dendritic cells from a heterogeneous cell population
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス,インコーポレーテッド 変異型Fc領域を含む抗体の同定および作製ならびにその利用法
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
JP2006517802A (ja) 2003-02-14 2006-08-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 外来性分子の一過性の発現もしくは安定な発現のための発現カセットおよび発現ベクター
EP1639014B1 (en) 2003-06-13 2010-09-22 Biogen Idec MA Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2005035557A2 (en) * 2003-10-14 2005-04-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB-特异性抗体及其使用方法
JP2007537753A (ja) * 2004-05-17 2007-12-27 ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 抗原でパルスされた、二重特異性抗体(BiAb)でコーティングされた樹状細胞の使用
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
HUE029465T2 (en) 2005-08-10 2017-02-28 Macrogenics Inc Identification and engineering of antibodies with variant Fc regions and methods of using same
US20080254047A1 (en) * 2007-02-23 2008-10-16 Baylor Research Institute Activation of Human Antigen-Presenting Cells Through CLEC-6
US8282964B2 (en) * 2007-10-27 2012-10-09 Medical Diagnostic Laboratories, Llc Ex-vivo treatment of peripheral plasmacytoid dendritic cells with IFN-lambda
US8163551B2 (en) 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
BRPI0921433A2 (pt) * 2008-10-31 2017-06-06 Abbott Biotherapeutics Corp uso de anticorpos anti-cs1 para o tratamento de linfomas raros
AR075989A1 (es) 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗cdcp1抗體
FR2968561B1 (fr) * 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire

Similar Documents

Publication Publication Date Title
JP2016505556A5 (https=)
EP3668898B1 (en) Humanized antibodies for cd3
US11352432B2 (en) Antibodies specifically binding to human IL-1R7
CN111484555B (zh) 新型双特异性cd3/cd20多肽复合物
JP2021524244A5 (https=)
JP2015533853A5 (https=)
JP2018519364A5 (https=)
RU2013125457A (ru) Комбинация антител против с-мет
HRP20201375T1 (hr) ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE
CN110536903A (zh) 抗ox40抗体及其用途
JP2012526558A5 (https=)
JP2013545738A5 (https=)
JP2018503380A5 (https=)
RU2010149746A (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
JP2022517441A (ja) Btla抗体
JP2020523038A5 (https=)
WO2021226591A1 (en) Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
JP2021533796A5 (https=)
JP2015509960A5 (https=)
JP2013519690A5 (https=)
JP7698635B2 (ja) 抗幹細胞因子抗体及びその使用方法
JP2025041695A (ja) 抗体および使用方法
JP2018529672A5 (https=)
CN116234826A (zh) Btla抗体
WO2023028162A1 (en) Antibodies targeting immunosuppressive b cells